As COVID pandemic drags on, focus turns to quest for universal coronavirus vaccine


Could a so-called “pan-coronavirus” vaccine be the long-awaited silver bullet that ends the COVID pandemic—and the next one, too?

Answer: It’s complicated.

“The term pan-coronavirus vaccine needs an asterisk next to it,” Dr. Stuart Ray, vice chair of medicine for data integrity and analytics at Johns Hopkins’ Department of Medicine, told Fortune.

Such a vaccine could tackle all coronaviruses, named for their crown-like appearance under a microscope. Or it could focus on COVID-19 and its myriad variants. Or it could tackle the four longstanding coronaviruses that circulate as common colds—or any combination thereof.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Whatever form such a vaccine might take, it’s a worthy goal, Dr. Bruce Walker—director of the Ragon Institute of MGH, MIT, and Harvard, a medical institute focused on eradicating disease, and co-leader of the Massachusetts Consortium on Pathogen Readiness—told Fortune.

But it may forever remain just that: a goal.

“I think we have to be aspirational in terms of aiming to make a pan-coronavirus vaccine, but it will not be an easy task,” Walker cautioned. “There’s not an obvious path forward.”

However pie-in-the-sky the goal may be, there’s no shortage of work being done to accomplish it. A universal coronavirus vaccine is a top research priority for nonprofits, government agencies, and vaccine-makers, according to an April article in Nature.

This is an excerpt. Read the original post here

Source link


Please enter your comment!
Please enter your name here